IP Library Granted Patent US 12,264,143
Granted Patent B2
US 12,264,143 · App. 18/750,852 · Granted Apr 1, 2025

Synthesis of cannabinoids and cannabinoid precursors, and related compounds, formulations, and methods of use

Inventors: Glenn M. Sammis (Vancouver, CA); Markus Roggen (Vancouver, CA)
Assignee: Nalu Bio, Inc.
C07D311/80A61K31/658C07C39/23C07C215/50C07D311/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,264,143
App. No.
18/750,852
Granted
Apr 1, 2025
Kind
B2
Abstract

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ 9 -tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

Claims (21)

1. A method for synthesizing a cannabinoid, wherein the method comprises:

(a) reacting an optionally substituted phloroglucinol reactant having the structure

with an electron-withdrawing hydroxyl-protecting reagent under conditions effective to provide a first intermediate comprising a hydroxyl-protected compound having the structure

wherein n is zero, 1 or 2; R 2 is selected from C 1 -C 12 alkyl, C 1 -C 12 alkoxy, C 2 -C 12 alkoxyalkyl, C 1 -C 12 alkylsulfanyl, C 2 -C 12 acyl, C 2 -C 12 acyloxy, C 2 -C 12 alkoxycarbonyl, C 6 -C 18 aryloxycarbonyl, carboxyl, and halo; and PR is a hydroxyl-protecting group;

(b) effecting a cross-coupling reaction between the first intermediate and a reactant R 1 -M in a solvent in the presence of a cross-coupling catalyst, wherein:

R 1 is selected from C 1 -C 12 alkyl; (C 1 -C 8 alkoxy)-substituted C 1 -C 12 alkyl; C 1 -C 12 alkyl substituted with N (C 1 -C 8 alkyl) 2 ; C 1 -C 12 alkyl substituted with C 1 -C 8 alkylsulfonyl (—SO 2 -alkyl); and C 1 -C 12 alkyl substituted with oxanyl, morpholino, or diazinanyl, and

M is selected from —Zn—X, —B(OH) 2 , —B(OR) 2 , —MgX and —CuLi in which X is halo and R is alkyl, thereby providing a second intermediate in which a protected hydroxyl group has been replaced with R 1 , the second intermediate having the structure

(c) hydrolyzing the second intermediate to remove the hydroxyl-protecting groups, thereby providing an R 1 -substituted deprotected compound as a third intermediate having the

(d) contacting the R 1 -substituted deprotected compound with a substituted cyclohexene reactant having the structure

wherein R 5 is H, carboxyl, C 2 -C 6 acyloxy, C 2 -C 6 alkoxycarbonyl, C 1 -C 6 alkyl, or C 1 -C 6 alkyl substituted with hydroxyl, carboxyl, or halo; R 8 is methyl, hydroxymethyl, or halomethyl; and L is a leaving group, in the presence of a Lewis acid catalyst under reaction conditions effective to result in coupling of the R 1 -substituted deprotected intermediate and the substituted cyclohexene reactant to provide a reaction product composition comprising a cannabinoid having the structure

2. The method of claim 1 , wherein R 1 -M is R 1 —MgBr, the cross-coupling catalyst is an iron-based catalyst, and the cross-coupling reaction is a Fürstner reaction carried out at a reaction temperature in the range of −25° C. to 25° C.

3. The method of claim 2 , wherein about 1 equivalent to about 1.5 equivalents of R 1 —MgBr are used and the reaction temperature in the range of −15° C. to −5° C.

4. The method of claim 1 , wherein the first intermediate is not isolated or purified prior to the cross-coupling reaction of step (b).

5. The method of claim 1 , wherein the third intermediate is not isolated or purified prior to step (d).

6. The method of claim 1 , wherein R 5 and R 8 are methyl, so that the cannabinoid in the reaction product composition has the structure

7. The method of claim 6 , wherein n is zero.

8. The method of claim 7 , wherein R 1 is n-pentyl, such that the R 1 -substituted deprotected compound is olivetol and the cannabinoid is cannabidiol (CBD).

9. The method of claim 7 , wherein R 1 is n-propyl, such that the R 1 -substituted deprotected compound is divarinol.

10. The method of claim 8 , wherein R 1 is n-pentyl and the method further comprises subjecting the cannabinoid to cyclization conditions.

11. The method of claim 6 , wherein the electron-withdrawing hydroxyl-protecting reagent converts hydroxyl groups to sulfonate esters.

12. The method of claim 11 , wherein the sulfonate esters are selected from tosylate, mesylate, triflate, benzyl sulfonate, 2-[(4-nitrophenyl) ethyl] sulfonate, and fluorosulfonate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2024
From: SAMMIS, GLENN M.; ROGGEN, MARKUS
To: NALU BIO, INC.
Reel/Frame 067935/0766 →
Continuity (4)
Continuation 18212061 · Jun 20, 2023
Continuation In Part PCTUS2021064243 · Dec 17, 2021
Provisional Application 63126923 · Dec 17, 2020
Related Publication 20240368108A1 · Nov 7, 2024
References Cited (33)
US 7186850B2 · Silverberg · 2007 [cited by applicant]
US 10053407B2 · Dickman et al. · 2018 [cited by applicant]
US 10059683B2 · Dialer et al. · 2018 [cited by applicant]
US 10399920B2 · Dickman et al. · 2019 [cited by applicant]
US 20170283837A1 · Kavarana et al. · 2017 [cited by applicant]
US 20200079715A1 · Davis et al. · 2020 [cited by applicant]
US 20200325091A1 · Porco et al. · 2020 [cited by applicant]
US 20220204431A1 · Shen et al. · 2022 [cited by applicant]
WO 2014062965A1 · 2014 [cited by applicant]
WO 2019046806A1 · 2019 [cited by applicant]
WO 2020102901A1 · 2019 [cited by applicant]
WO 2020031179A1 · 2020 [cited by applicant]
WO 2020099283A1 · 2020 [cited by applicant]
WO 2020229891A1 · 2020 [cited by applicant]
WO 2021007661A1 · 2021 [cited by applicant]
Furstner et al. (Angew. Chem. Int. Ed., vol. 41 (4), pp. 609-612 (2002)). [cited by examiner]
CAPLUS Abstract—Bezmenova and Kamakin, “Reaction of Sulfolane and its derivatives with a Grignard Reagent” Khimiya Seraorganicheskikh Soedinenii, Soderzhashchikhsya v Neftyakh i Nefteproduktakh, vol. 8, pp. 140-144 (196… [cited by examiner]
Oda and Yamamoto, “Reaction of Dimethyl Sulfoxide with Grignard Reagents” (J. Org. Chem. vol. 26, pp. 4679-4681 (1961)). [cited by examiner]
Gong et al., “Synthesis of CBD and Its Derivatives Bearing Various C4′-Side Chains with a Late-Stage Diversification Method,” J. Org. Chem. 2020, 85, 2704-2715. [cited by applicant]
Kinney et al., “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability,” ACS Med. Chem. Lett. 2016, 7, 424-428. [cited by applicant]
Qi et al., “Delta9-Tetrahydrocannabinol Immunochemical Studies: Haptens, Monoclonal Antibodies, and a Convenient Synthesis of Radiolabeled Delta9-Tetrahydrocannabinol,” J. Med. Chem. 2005, 48, 7389-7399. [cited by applicant]
Ben-Shabat et al. (2006), “New Cannabidiol Derivatives: Synthesis, Binding to Cannabinoid Receptor, and Evaluation of their Antiinflammatory Activity,” J. Med. Chem. 49: 1113-1117. [cited by applicant]
Barker et al., “The Synthesis of Olivetol. Trimethylsilation as a Protective Group During Grignard Reactions,” Organic Prep. and Procedures Int'l: The New J. Org. Synth. 11(2): 87-92. [cited by applicant]
Campeau et al. (2019), “Cross-Coupling and Related Reactions: Connecting Past Success to the Development of New Reactions for the Future,” Organometallics 38(1): 3-35. [cited by applicant]
Götz (2019), “Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives,” Frontiers in Pharmacology 10: 1284. [cited by applicant]
Haj et al. (2015), “HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid,” J. Pharmacol. Exper. Ther. 355: 66-75. [cited by applicant]
Heiskanen et al. (2008), “4-Aryl-8-hydroxyquinolines from 4-chloro-8-tosyloxyquinoline using a Suzuki-Miyaura Cross-Coupling Approach,” Tetrahedron 65: 518-524. [cited by applicant]
Jung et al. (2019), “Synthetic Strategies for (-)-Cannabidiol and its Structural Analogs,” Chem. Asian J. 14:3749-3762. [cited by applicant]
Lago-Fernandez et al. (2017), “New Methods for the Synthesis of Cannabidiol Derivatives,” Methods in Enzymology 593: 237-257. [cited by applicant]
Morales et al. (2017), “An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol,” Frontiers in Pharmacology 8(422): 1-18. [cited by applicant]
Seltzman et al. (1991), “Synthesis of Nona-Deutero Olivetol and Nona-Deutero Cannabinoids,” J. Labeled Compounds and Radiopharm. XXIX(9): 1009-1018. [cited by applicant]
Stern et al. (2007), “Medicinal Chemistry Endeavors around the Phytocannabinoids,” Chemistry & Biodiversity 4: 1707-1728. [cited by applicant]
Mechoulam et al. (2002), “Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects,” Chem. Phys. Lipids 121: 35-43. [cited by applicant]